Kayfanda

Odevixibat, the active ingredient in Kayfanda, is an Ileal bile acid transporter (IBAT) inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of cholestatic liver disorders such as progressive familial intrahepatic cholestasis type 2 and Alagille syndrome, helping to lower bile acid accumulation in affected patients.

GNH USA supplies Kayfanda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kayfanda acts on the bile acid transport pathway to manage cholestatic liver disease. - Progressive familial intrahepatic cholestasis type 2 (PFIC2): reduces serum bile acid levels and improves liver function. - Alagille syndrome: lowers bile acid accumulation and supports hepatic health. - Other cholestatic liver diseases: may decrease bile acid overload and alleviate related symptoms.

Adverse reactions have been reported with odevixibat therapy.

Common Side Effects: - Diarrhea: loose stools occurring during treatment. - Abdominal pain: discomfort or cramping in the stomach region. - Nausea: feeling of queasiness that may lead to vomiting. - Fatigue: reduced energy levels or tiredness.

Serious or Rare Side Effects: - Severe liver injury: marked elevation of liver enzymes requiring medical attention. - Cholestatic hepatitis: inflammation of the liver associated with bile flow obstruction. - Allergic reactions: rash, itching, swelling, or difficulty breathing indicating hypersensitivity.

Before initiating therapy, clinicians should consider several safety measures. - Dose adjustment: monitor liver function tests regularly to guide dosing. - Renal function: assess renal parameters before starting treatment. - Pediatric use: administer only under specialist supervision. - Pregnancy: evaluate risk‑benefit ratio; limited data are available. - Drug interactions: review concomitant bile‑acid sequestrants and other agents. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Odevixibat may interact with other medicines that affect bile acid metabolism or absorption.

Major Interactions (Avoid): - Bile acid sequestrants: can bind odevixibat and markedly reduce its absorption. - Strong CYP3A4 inhibitors: may increase systemic exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Antibiotics altering gut flora: may modify enterohepatic circulation and affect efficacy. - High‑fat meals: can decrease oral absorption of odevixibat. - Other IBAT inhibitors: additive reduction of bile acids may increase risk of liver‑related events.